Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease evolution and heterogeneity in bilateral breast cancer.
Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G. Fountzilas E, et al. Among authors: pectasides d. Am J Cancer Res. 2016 Nov 1;6(11):2611-2630. eCollection 2016. Am J Cancer Res. 2016. PMID: 27904775 Free PMC article.
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Fountzilas G, et al. Among authors: pectasides d. Breast Cancer Res Treat. 2005 Jul;92(1):1-9. doi: 10.1007/s10549-005-0322-y. Breast Cancer Res Treat. 2005. PMID: 15980985 Clinical Trial.
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G, Aravantinos G. Skarlos DV, et al. Among authors: pectasides d. Anticancer Res. 2005 Jul-Aug;25(4):3103-8. Anticancer Res. 2005. PMID: 16080573 Free article. Clinical Trial.
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N. Pentheroudakis G, et al. Among authors: pectasides d. Breast Cancer Res Treat. 2006 Jun;97(3):237-44. doi: 10.1007/s10549-005-9117-4. Epub 2005 Dec 2. Breast Cancer Res Treat. 2006. PMID: 16322882
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, Dimopoulos MA, Skarlos D, Fountzilas G. Kostopoulos I, et al. Among authors: pectasides d. Breast Cancer Res Treat. 2006 Apr;96(3):251-61. doi: 10.1007/s10549-005-9062-2. Breast Cancer Res Treat. 2006. PMID: 16538542 Clinical Trial.
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival.
Kostadima L, Pentheroudakis G, Fountzilas G, Dimopoulos M, Pectasides D, Gogas H, Stropp U, Christodoulou C, Samantas E, Wirtz R, Hennig G, Bafaloukos D, Arapantoni P, Kalofonos H, Papakostas P, Economopoulos T, Bamias A, Pavlidis N. Kostadima L, et al. Among authors: pectasides d. Breast Cancer Res Treat. 2006 Nov;100(2):161-7. doi: 10.1007/s10549-006-9240-x. Epub 2006 Jul 18. Breast Cancer Res Treat. 2006. PMID: 16823513
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G, Plataniotis G, Misailidou D, Bobos M, Pectasides D, Razis E, Karavelis A, Selviaridis P. Fountzilas G, et al. Among authors: pectasides d. Anticancer Res. 2006 Nov-Dec;26(6C):4675-86. Anticancer Res. 2006. PMID: 17214326 Free article. Clinical Trial.
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
Kosmidis PA, Dimopoulos MA, Syrigos K, Nicolaides C, Aravantinos G, Boukovinas I, Pectasides D, Fountzilas G, Bafaloukos D, Bacoyiannis C, Kalofonos HP. Kosmidis PA, et al. Among authors: pectasides d. J Thorac Oncol. 2007 Feb;2(2):135-40. J Thorac Oncol. 2007. PMID: 17410029 Free article. Clinical Trial.
329 results